Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata

Last Updated:
05/09/2016
Status:
Completed
Country:
United States
Eligibility:
Age 18-75; patch type alopecia areata
Drug:
Ruxolitinib
Administration:
Oral
Sponsor: 
Columbia University

This study has been completed and results are pending.

Many people in the U.S. suffer from alopecia areata, yet treatment options are limited and sometimes painful. The goal of this study is to test a new medication taken as a pill that acts on the immune system and may reverse hair loss.

New York Presbyterian Hospital
Columbia University
New York, New York